Interleukin 33 (IL33) Antibody

286€ (100 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Interleukin 33 (IL33) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx131855
tested applications
WB, IHC, IF/ICC
Description
Interleukin 33 Antibody is a Mouse Monoclonal against Interleukin 33.
Documents del producto
Instrucciones
Data sheet
Product specifications
Category | Primary Antibodies |
Immunogen Target | Interleukin 33 (IL33) |
Host | Mouse |
Reactivity | Human |
Recommended Dilution | WB: 0.01-2 µg/ml, IHC: 5-20 µg/ml, IF/ICC: 5-20 µg/ml. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Monoclonal |
Conjugation | Unconjugated |
Isotype | IgG2a Kappa |
Purification | Purified by Protein A and Protein G affinity chromatography. |
Size 1 | 100 µl |
Size 2 | 200 µl |
Size 3 | 1 ml |
Form | Liquid |
Tested Applications | WB, IHC, IF/ICC |
Buffer | 0.01 M PBS, pH 7.4, containing 0.05% Proclin-300, 50% glycerol. |
Availability | Shipped within 5-7 working days. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | O95760 |
Alias | IL33,IL-33,C9orf26,IL1F11,IL-1F11 |
Background | Antibody anti-IL33 |
Status | RUO |
Descripción
IL33 is a nuclear alarmin cytokine belonging to the IL-1 family, released during cellular stress, injury, or necrosis to alert the immune system and promote inflammation. IL33 binds to its receptor IL1RL1 (ST2) and forms a signaling complex with IL1RAP, leading to activation of NF-κB and MAPK pathways, which drive cytokine production, immune cell activation, and tissue repair. IL33 primarily targets type 2 immune cells, including Th2 cells, innate lymphoid cells (ILC2s), mast cells, and eosinophils, to regulate allergic inflammation, tissue homeostasis, and anti-helminth immunity. It is abundantly expressed in epithelial cells, endothelial cells, and fibroblasts, where it functions as both a cytokine and a transcriptional regulator. Dysregulated IL33 signaling contributes to allergic diseases, such as asthma, atopic dermatitis, and rhinitis, as well as inflammatory and fibrotic disorders. In tumors, IL33 can promote both pro- and anti-tumor immune responses depending on the context. Knockout studies reveal reduced type 2 cytokine production, impaired tissue repair, and weakened immune responses, highlighting IL33’s role in inflammation, tissue homeostasis, and immunity.
Related Products

Human IL-33(Interleukin-33) ELISA Kit
Ver Producto
Mouse IL-33(Interleukin 33) ELISA Kit
Ver Producto